A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed

to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence

inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.

Key Features:

• Rare disease.

• Drug development.

• Innovative clinical trial design.

• Regulatory approval.

• Real-world evidence.

A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed

to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence

inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.

Key Features:

• Rare disease.

• Drug development.

• Innovative clinical trial design.

• Regulatory approval.

• Real-world evidence.

Collaborative innovation networks are cyberteams of motivated individuals, and are self-organizing emergent social systems with the potential to promote health, happiness and individual growth in real-world work settings.

This book describes how to identify and nurture collaborative innovation networks in order to shape the future working environment and pave the way for health and happiness, and how to develop future technologies to promote economic development, social innovation and entrepreneurship. The expert contributions and case studies presented also offer insights into how large corporations can creatively generate solutions to real-world problems by means of self-organizing mechanisms, while simultaneously promoting the well-being of individual workers. The book also discusses how such networks can benefit startups, offering new self-organizing forms of leadership in which all stakeholders are encouraged to collaborate in the development of new products.

This book explores China''s hukou system, by which individuals are registered in a specific geographic region, and the prospects for reform. The history of the hukou system and its instrumental role in Chinese urbanization and labor markets is explained, and readers get a sense of what issues are prioritized by Chinese policymakers as they contemplate reform or change to this system, from hukou-based labor market discrimination, inequality of opportunity, multi-dimensional poverty of rural migrants, the public health consequences of non-hukou migration, and old age insurance for migrants without hukous. The author concludes with a stirring and practical call for hukou reform, articulating a cost-benefit model and providing an array of policy suggestions. This book will interest scholars of Chinese society, demographics and future urbanization. 

A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed

to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence

inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.

Key Features:

• Rare disease.

• Drug development.

• Innovative clinical trial design.

• Regulatory approval.

• Real-world evidence.

A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed

to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence

inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.

Key Features:

• Rare disease.

• Drug development.

• Innovative clinical trial design.

• Regulatory approval.

• Real-world evidence.

Collaborative innovation networks are cyberteams of motivated individuals, and are self-organizing emergent social systems with the potential to promote health, happiness and individual growth in real-world work settings.

This book describes how to identify and nurture collaborative innovation networks in order to shape the future working environment and pave the way for health and happiness, and how to develop future technologies to promote economic development, social innovation and entrepreneurship. The expert contributions and case studies presented also offer insights into how large corporations can creatively generate solutions to real-world problems by means of self-organizing mechanisms, while simultaneously promoting the well-being of individual workers. The book also discusses how such networks can benefit startups, offering new self-organizing forms of leadership in which all stakeholders are encouraged to collaborate in the development of new products.

This book explores China''s hukou system, by which individuals are registered in a specific geographic region, and the prospects for reform. The history of the hukou system and its instrumental role in Chinese urbanization and labor markets is explained, and readers get a sense of what issues are prioritized by Chinese policymakers as they contemplate reform or change to this system, from hukou-based labor market discrimination, inequality of opportunity, multi-dimensional poverty of rural migrants, the public health consequences of non-hukou migration, and old age insurance for migrants without hukous. The author concludes with a stirring and practical call for hukou reform, articulating a cost-benefit model and providing an array of policy suggestions. This book will interest scholars of Chinese society, demographics and future urbanization.